藥明康德(603259.SH):子公司擬出資10億元認購藥明匯英基金份額
格隆匯5月20日丨藥明康德(603259.SH)公佈,公司的全資子公司上海藥明康德新藥開發有限公司(簡稱“上海藥明康德”)擬參加蘇州藥明匯英一期產業投資基金合夥企業(有限合夥)(簡稱“藥明匯英基金”)的資金募集,其中上海藥明康德擬認購基金份額人民幣10億元。公司副董事長、全球首席投資官Edward Hu(胡正國)在藥明匯英基金擔任執行事務合夥人委派代表。
藥明匯英基金的目標募集規模為人民幣100億元,上海藥明康德擬持有藥明匯英基金份額的10%。藥明匯英基金為公司合資設立的私募基金管理公司藥明匯聚(私募基金管理人登記編碼:P1071937)所募集、管理的產業投資併購基金,擬以大中華地區醫療產業結構性成長機遇為導向,致力於對醫療健康領域的中後期標的進行產業投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.